Tags

Type your tag names separated by a space and hit enter

Xylans from Scinaia hatei: Structural features, sulfation and anti-HSV activity.
Int J Biol Macromol. 2010 Mar 01; 46(2):173-8.IJ

Abstract

Natural compounds offer interesting pharmacological perspectives for antiviral drug development with regard to broad-spectrum antiviral properties and novel modes of action. In this study, we have analyzed alkali-extracted xylan of Scinaia hatei. Alkali extraction of this red alga yielded a xylan shown to have a molecular mass of 120kDa and a linear structure of (1-->4)-linked beta-d-xylopyranosyl residues. Derivatives (S1, S2, S3 and S4) generated by chemical sulfation from this macromolecule had degree of sulfation between 0.93 and 1.95, and contained strong anti-HSV activity with inhibitory concentration 50% (IC(50)) from 0.22 to 1.37mug/ml. Furthermore, they had no direct inactivating effect on virions in a virucidal assay. Sulfate groups account for their in vitro antiviral activity. Interestingly, sulfated xylans already exerted anti-HSV activity when only pre-incubated with the cultured cells prior to infection, thus pointing to a main inhibitory effect on viral entry.

Authors+Show Affiliations

Natural Products Laboratory, Department of Chemistry, The University of Burdwan, Golapbag, Burdwan, WB 713104, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20026104

Citation

Mandal, Pinaki, et al. "Xylans From Scinaia Hatei: Structural Features, Sulfation and anti-HSV Activity." International Journal of Biological Macromolecules, vol. 46, no. 2, 2010, pp. 173-8.
Mandal P, Pujol CA, Damonte EB, et al. Xylans from Scinaia hatei: Structural features, sulfation and anti-HSV activity. Int J Biol Macromol. 2010;46(2):173-8.
Mandal, P., Pujol, C. A., Damonte, E. B., Ghosh, T., & Ray, B. (2010). Xylans from Scinaia hatei: Structural features, sulfation and anti-HSV activity. International Journal of Biological Macromolecules, 46(2), 173-8. https://doi.org/10.1016/j.ijbiomac.2009.12.003
Mandal P, et al. Xylans From Scinaia Hatei: Structural Features, Sulfation and anti-HSV Activity. Int J Biol Macromol. 2010 Mar 1;46(2):173-8. PubMed PMID: 20026104.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Xylans from Scinaia hatei: Structural features, sulfation and anti-HSV activity. AU - Mandal,Pinaki, AU - Pujol,Carlos Alberto, AU - Damonte,Elsa Beatriz, AU - Ghosh,Tuhin, AU - Ray,Bimalendu, Y1 - 2009/12/21/ PY - 2009/08/28/received PY - 2009/11/25/revised PY - 2009/12/09/accepted PY - 2009/12/23/entrez PY - 2009/12/23/pubmed PY - 2010/5/14/medline SP - 173 EP - 8 JF - International journal of biological macromolecules JO - Int J Biol Macromol VL - 46 IS - 2 N2 - Natural compounds offer interesting pharmacological perspectives for antiviral drug development with regard to broad-spectrum antiviral properties and novel modes of action. In this study, we have analyzed alkali-extracted xylan of Scinaia hatei. Alkali extraction of this red alga yielded a xylan shown to have a molecular mass of 120kDa and a linear structure of (1-->4)-linked beta-d-xylopyranosyl residues. Derivatives (S1, S2, S3 and S4) generated by chemical sulfation from this macromolecule had degree of sulfation between 0.93 and 1.95, and contained strong anti-HSV activity with inhibitory concentration 50% (IC(50)) from 0.22 to 1.37mug/ml. Furthermore, they had no direct inactivating effect on virions in a virucidal assay. Sulfate groups account for their in vitro antiviral activity. Interestingly, sulfated xylans already exerted anti-HSV activity when only pre-incubated with the cultured cells prior to infection, thus pointing to a main inhibitory effect on viral entry. SN - 1879-0003 UR - https://www.unboundmedicine.com/medline/citation/20026104/Xylans_from_Scinaia_hatei:_Structural_features_sulfation_and_anti_HSV_activity_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0141-8130(09)00266-9 DB - PRIME DP - Unbound Medicine ER -